Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
Jung CW, Shih LY, Xiao Z, Jie J, Hou HA, Du X, Wang MC, Park S, Eom KS, Oritani K, Okamoto S, Tauchi T, Kim JS, Zhou D, Saito S, Li J, Handa H, Jianyong L, Ohishi K, Hou M, Depei W, Takenaka K, Liu T, Hu Y, Amagasaki T, Ito K, Gopalakrishna P, Akashi K. Jung CW, et al. Among authors: eom ks. Leuk Lymphoma. 2015 Jul;56(7):2067-74. doi: 10.3109/10428194.2014.969260. Epub 2014 Nov 20. Leuk Lymphoma. 2015. PMID: 25315076 Clinical Trial.
Hematopoietic stem cell transplant following remission induction chemotherapy including gemtuzumab ozogamicin is a feasible and effective treatment option in elderly patients with acute myeloid leukemia.
Eom KS, Kim HJ, Cho BS, Choi SM, Lee DG, Lee SE, Yahng SA, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Park CW, Min WS. Eom KS, et al. Leuk Lymphoma. 2011 Dec;52(12):2321-8. doi: 10.3109/10428194.2011.587562. Epub 2011 Oct 24. Leuk Lymphoma. 2011. PMID: 22023488
The 2020 revision of the guidelines for the management of myeloproliferative neoplasms.
Kim SY, Bae SH, Bang SM, Eom KS, Hong J, Jang S, Jung CW, Kim HJ, Kim HY, Kim MK, Kim SJ, Mun YC, Nam SH, Park J, Won JH, Choi CW. Kim SY, et al. Among authors: eom ks. Korean J Intern Med. 2021 Jan;36(1):45-62. doi: 10.3904/kjim.2020.319. Epub 2020 Dec 4. Korean J Intern Med. 2021. PMID: 33147902 Free PMC article. Review.
Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study.
Eom KS, Kim SJ, Lee JJ, Suh C, Kim JS, Yoon SS, Kim BS, Kang HJ, Choi YJ, Kim CS, Kim YS, Kwak JY, Kim YJ, Joo YD, Mun YC, Jo DY, Park JS, Park CY, Kim SH, Min CK. Eom KS, et al. Biomed Res Int. 2014;2014:245247. doi: 10.1155/2014/245247. Epub 2014 Jun 23. Biomed Res Int. 2014. PMID: 25050331 Free PMC article. Clinical Trial.
Genetic-pathologic characterization of myeloproliferative neoplasms.
Kim Y, Park J, Jo I, Lee GD, Kim J, Kwon A, Choi H, Jang W, Chae H, Han K, Eom KS, Cho BS, Lee SE, Yang J, Shin SH, Kim H, Ko YH, Park H, Jin JY, Lee S, Jekarl DW, Yahng SA, Kim M. Kim Y, et al. Among authors: eom ks. Exp Mol Med. 2016 Jul 22;48(7):e247. doi: 10.1038/emm.2016.55. Exp Mol Med. 2016. PMID: 27444979 Free PMC article.
Prognostic Prediction Model for Second Allogeneic Stem-Cell Transplantation in Patients With Relapsed Acute Myeloid Leukemia: Single-Center Report.
Park SS, Kim HJ, Min KI, Min GJ, Jeon YW, Yoon JH, Yahng SA, Shin SH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS. Park SS, et al. Among authors: eom ks. Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):e167-e182. doi: 10.1016/j.clml.2018.02.009. Epub 2018 Feb 17. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29519618
408 results